PROTEIN EXPRESSED SPECIFICALLY IN OVARIAN CLEAR CELL ADENOCARCINOMA AND USE APPLICATIONS THEREOF

WIPO Patent Application WO/2011/102461

A1

A protein produced specifically by an ovarian clear cell adenocarcinoma cell is searched, and the use applications of the protein are established. Specifically disclosed are: a method for evaluating and/or identifying clear cell adenocarcinoma, which comprises measuring the expression of at least one protein selected from the group consisting of tissue factor pathway inhibitor-2, ceruloplasmin, insulin-like growth factor binding protein-1, doublecortin-containing protein-2, N-Myc down-regulation gene-1, ribonuclease-T2, growth differentiation factor-15, versican core protein, laminin subunit gamma-1, sponging-1, insulin-like growth factor binding protein-7, interleukin-6 and osteopontin in a biological sample; a kit for the evaluation and/or identification of clear cell adenocarcinoma; a method for identifying a substance that is effective for the treatment and/or prevention of clear cell adenocarcinoma; and a method for identifying a substance that can reduce the anticancer agent resistance of clear cell adenocarcinoma.

ARAKAWA NORIAKI (JP)
MASUISHI YUSUKE (JP)
YAMANAKA YUKO (JP)
HIRANO HISASHI (JP)
KAWASAKI HIROSHI (JP)
HIRAHARA FUMIKI (JP)
MIYAGI ETSUKO (JP)

PCT/JP2011/053497

August 25, 2011

February 18, 2011

Click for automatic bibliography generation  

PUBLIC UNIV CORP YOKOHAMA CITY (JP)
ARAKAWA NORIAKI (JP)
MASUISHI YUSUKE (JP)
YAMANAKA YUKO (JP)
HIRANO HISASHI (JP)
KAWASAKI HIROSHI (JP)
HIRAHARA FUMIKI (JP)
MIYAGI ETSUKO (JP)

G01N33/68; C12N15/09; C12Q1/68; G01N33/15; G01N33/50; G01N33/574

JP2009100737A	2009-05-14
JP2005073548A	2005-03-24

THOMAS, R. ET AL.: "Placental bone morphogenetic protein (PLAB) gene expression in normal, pre- malignant and malignant human prostate: Relation to tumor development and progression.", INT.J.CANCER, vol. 93, no. 1, 2001, pages 47 - 52
KARAN, D. ET AL.: "Dysregulated expression of MIC-1/PDF in human prostate tumor cells", BIOCHEM.BIOPHYS.RES.COMMUN., vol. 305, no. 3, 2003, pages 598 - 604
NORIOMI MATSUMURA: "Development of Chemosensitivity Biomarkers and Identification of Specific Molecular Target in Ovarian Cancer : Genome-wide Approach Using Bioinformatics", ACTA OBSTETRICA ET GYNAECOLOGIA JAPONICA, vol. 61, no. 11, 2009, pages 2013 - 2026
HIROSHI TSUDA ET AL.: "Ransogan no Atarashii Yogo Inshi to Biomarker Microarray o Mochiita Atarashii Yogo Inshi ya Biomarker Tansaku Meisaibosengan", OBSTETRICAL AND GYNECOLOGICAL PRACTICE, vol. 55, no. 13, 2006, pages 2167 - 2171
AKIRA HIRASAWA ET AL.: "Ranso Meisaibosengan no Yogo Kanren Biomarker no Morateki Tansaku", ACTA OBSTETRICA ET GYNAECOLOGIA JAPONICA, vol. 58, no. 2, 2006, pages 621
HISASHI HIRANO ET AL.: "Genome kara Proteome e", NIPPON BYORI GAKKAI KAISHI, vol. 97, no. 2, 2008, pages 20
NORIAKI ARAKAWA ET AL.: "Ranso Meisaibosengan ga Tokuiteki ni Sansei Shiteiru Tanpakushitsu no Tansaku to Kino Kaiseki", JOURNAL OF JAPANESE BIOCHEMICAL SOCIETY, 2007, pages 4P-0930
ETSUKO MIYAGI ET AL.: "Proteome Kaiseki ni yoru Ranso Meisaibosengan Tokuiteki Tanpakushitsu no Dotei", ACTA OBSTETRICA ET GYNAECOLOGIA JAPONICA, vol. 57, no. 2, 2005, pages 458

MAYAMA, Setsuko et al. (JP)
Setsuko Mayama (JP)

View/Download PDF      PDF Help

Previous Patent: PROPHYLACTIC OR THERAPEUTIC AGENT FOR GASTRIC ULCER, MEDICINAL AGENT FOR ORAL ADMINISTRATION, AND PR...

Next Patent: MODIFIED HYALURONIC ACID AND/OR SALT THEREOF, METHOD FOR PRODUCING SAME AND COSMETIC COMPRISING SAME